Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=458 Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
Carcinoma, Hepatocellular
Primary: Time to Progression (TTP) — 164; 112 days
Phase 2 N=47 Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
Hepatocellular Carcinoma · Liver Cancer
Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months
Phase 3 N=720 Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Overall Survival — 289; 259 Days
Phase 3 N=356 Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Advanced Adult Hepatocellular Carcinoma · Recurrent Hepatocellular Carcinoma · Stage III Hepatocellular Carcinoma AJCC v7
Primary: Overall Survival — 8.9; 10.5 month — p=0.24
Phase 2 N=24 Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)
Hepatocellular Carcinoma
Primary: Rate of Adverse Events (AE) ≥ Grade 3 (CTCAE 5.0) Excluding Palmar-plantar Erythrodysesthesia — 16 Participants
Phase 3 N=501 A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Overall Survival (OS) in the Global Population — 13.24; NA; 13.40; 19.22 months — p=0.0006
Phase 1 N=6 MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.
Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) — 1; 0 Participants
Phase 2 N=60 Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib
Hepatocellular Carcinoma
Primary: Overall Response Rate — 6; 30; 17; 0 Participants
Phase 2 N=16 Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer
Stage III Hepatocellular Carcinoma AJCC v8 · Stage IIIA Hepatocellular Carcinoma AJCC v8 · Stage IIIB Hepatocellular Carcinoma AJCC v7
Primary: Maximum Tolerated Dose (MTD) (Part 1 Only) — 400 milligrams (mg) once per day
Phase 2 N=50 SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
Primary: Disease Control Rate (DCR) at 16 Weeks for Patients Treated With Guadecitabine After Failure of Sorafenib — 25.0; 24.4 percentage of patients
Phase 2 N=24 Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Liver Cancer
Primary: Maximum Tolerated Dose (Phase I) — 2; 3; 0; 0 Participants
Phase 2 N=137 A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
Hepatocellular Carcinoma (HCC)
Primary: Progression Free Survival (PFS) Rate at 6 Months Per Independent Response Review Committee (IRRC) in Cohort A — 22.4 Percent of participants
Phase 2 N=41 Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
Liver Cancer
Primary: Response Rate by Recist Criteria — 6 participants
Phase 2 N=29 Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Disease Control Rate (DCR) in Study Participants — 46 percentage of participants
Phase 2 N=24 Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Advanced Adult Hepatocellular Carcinoma
Primary: Time to Progression (TTP) — 3.5 months
Phase 2 N=117 Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Phase 1b: Number of Participants Experiencing Dose Limiting Toxicity — 0; 0; 0 Participants
Phase 2 N=220 A Study to Evaluate SHR-1210 in Subjects With Advanced HCC
Hepatocellular Carcinoma Non-Resectable
Primary: Objective Response Rate — 11.9; 16.7 percentage of participants
N/A N=131 Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC
Advanced Hepatocellular Carcinoma
Primary: Percentage of Lesions With Organ-specific Response — 29.8; 28.3; 40.5; 29.1 Percentage of Units (lesions)
Phase 2 N=21 Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Number of Participants Who Remained Free of Progression at the 27th Week. — 21 participants — p=0.0006
Phase 3 N=684 A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma (HCC)
Primary: Safety Run-in Sub-study: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 8; 1 Participants
Phase 2 N=66 c-Met Second-Line Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Phase 1b: Number of Participants Experiencing Dose Limiting Toxicity (DLT) According to National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) for Adverse Events…
Phase 2 N=32 Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Number of Participants With Objective Response Rate — 20; 9; 0; 1 Participants
Phase 3 N=383 Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
Hepatocellular Carcinoma
Primary: Median Overall Survival (OS) Following Treatment With Tivantinib 120 mg BID Compared to Placebo Group in Participants With MET Diagnostic-High Inoperable Hepatocellular…
Phase 3 N=546 Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.
Carcinoma
Primary: Overall Survival (OS) — 7.56; 7.33 Months
Phase 2 N=27 Sorafenib and TRC105 in Hepatocellular Cancer
Hepatoma · Liver Neoplasms · Adenoma, Liver Cell
Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 When Given With Standard-dose Sorafenib for Hepatocellular Cancer (HCC) — 15 mg/kg
Phase 2 N=29 Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Median Time to Progression (TTP) — 3.7 months
Phase 2 N=249 Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
Hepatocellular Carcinoma (HCC)
Primary: Objective Response Rate (ORR) Assessed by Independent Review Committee (IRC) — 12.9 Percentage of participants — p=0.0001
Phase 3 N=707 Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Hepatocellular Carcinoma
Primary: Overall Survival (OS) — 10.2; 8.0 months — p=0.0049
Phase 2 N=95 Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Hepatocellular Carcinoma
Primary: Overall Response Rate (ORR) Per RECIST 1.1 by Central Assessment — 5.9; 11.1; 7.4; 14.8 Percentage of participants